On this page
This entry or formulation may be investigational and may not correspond to an FDA-approved product; safety and efficacy may not have been established. Kairo lists it for identification and record-keeping only.
Overview
Product & regulatory status
Research material; identity-specific evidence is essential.
The E-domain question
Researchers are investigating whether an IGF-1 E-domain peptide has biological actions distinct from mature IGF-1. Published experiments disagree about some claimed activities. [1]
What the evidence shows
Positive preclinical finding
A synthetic MGF E-domain peptide reduced cell-death measures and preserved aspects of heart function in a mouse myocardial-infarction experiment. This was not a human muscle-recovery study. [2]
Failed replication of muscle claims
Another research group could not reproduce claimed effects on proliferation or differentiation in human and mouse muscle cells. The study challenges simple claims that MGF reliably activates muscle stem cells. [1]
What remains unknown
The evidence does not establish a human recovery benefit, safe exposure, or equivalence between endogenous IGF variants and synthetic MGF products.
Safety
Clinical safety not answered
Cell and mouse experiments cannot characterize adverse effects of repeated use in people. Uncertainty about the active molecular form adds another limitation. [1]
Do not substitute PEG-MGF evidence
FDA evaluates PEG-MGF as a distinct preparation. Evidence for an MGF fragment cannot establish the safety of a modified PEG-MGF product. [3]
Understanding product quality
Compounded drugs are not FDA-approved finished products. Poor preparation can cause contamination or incorrect strength. A catalog entry or a research paper is not a quality assessment of your product. [4]
When to seek urgent help
Severe allergic symptoms such as trouble breathing, throat or tongue swelling, or fainting need immediate help. Call 911 or your local emergency number. This is general emergency information, not a complete list of risks for this compound. [5]
A starting point for discussion
This is not a complete list of adverse effects or interactions. Your health history, other medicines, and the exact formulation matter. Missing safety data is not evidence of safety.
Common questions
Why do sources use MGF in different ways?
Some discuss gene expression or an IGF-1 precursor, while others administer a synthetic fragment. Always check what was actually tested.
Questions for your clinician
Does the evidence match my condition and this exact product? What risks or interactions matter for me? How would we assess whether it is helping?
Sources
- Mechano-growth factor peptide, the COOH terminus of unprocessed insulin-like growth factor 1, has no apparent effect on myoblasts or primary muscle stem cells2014 · Primary research · PubMed
- The E-domain region of mechano-growth factor inhibits cellular apoptosis and preserves cardiac function during myocardial infarction2013 · Primary research · PubMed
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety RisksFDA · Compound-specific safety assessment
- Compounding and the FDA: Questions and AnswersFDA · product quality and regulation
- AnaphylaxisMedlinePlus · recognizing an emergency
Educational information, not a recommendation to use a compound. Kairo does not give dosing advice. Review decisions with a licensed healthcare professional.